Preferential human epidermal growth factor receptor 2 expression in myometrial and lymphovascular invasion of a uterine carcinosarcoma: A case report.
Obstetrics/gynecology
endometrial carcinosarcoma
endometrial serous carcinoma
human epidermal growth factor receptor 2
lymphovascular invasion
myometrial invasion
oncology
pathology
Journal
SAGE open medical case reports
ISSN: 2050-313X
Titre abrégé: SAGE Open Med Case Rep
Pays: England
ID NLM: 101638686
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
10
2021
accepted:
29
01
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
This case report describes a unique pattern of human epidermal growth factor receptor 2 expression in a patient with uterine carcinosarcoma. The endometrial tumor showed biphasic morphology composed of serous carcinoma and a heterologous high-grade sarcoma component. Human epidermal growth factor receptor 2 immunostaining showed positive (3+) expression in foci of myoinvasion, lymphovascular invasion, and lymph node metastasis but was negative in both the endometrial surface tumor and sarcomatous component. Fluorescent in situ hybridization testing for human epidermal growth factor receptor 2 confirmed no amplification within the endometrial surface carcinoma component and amplification of the lymphovascular invasion component. As the use of human epidermal growth factor receptor 2 immunohistochemical evaluation becomes more commonplace for therapeutic consideration in patients with uterine carcinosarcoma, interpretation of the immunohistochemical should be performed preferentially on large tissue sections including both a surface, myoinvasive portions, and suspected areas of lymphovascular invasion and lymph node metastasis.
Identifiants
pubmed: 35273799
doi: 10.1177/2050313X221081361
pii: 10.1177_2050313X221081361
pmc: PMC8902189
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2050313X221081361Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):416-22
pubmed: 16445668
Gynecol Oncol. 2010 Jan;116(1):15-20
pubmed: 19840887
Virchows Arch. 2021 Jun;478(6):1161-1171
pubmed: 33423127
Br J Cancer. 2018 Feb 6;118(3):378-387
pubmed: 29169184
Pathobiology. 2018;85(1-2):35-40
pubmed: 28614814
Cancer Sci. 2003 Nov;94(11):986-91
pubmed: 14611676
Arch Pathol Lab Med. 2021 Jun 1;145(6):687-691
pubmed: 32649220
J Clin Oncol. 2018 Jul 10;36(20):2044-2051
pubmed: 29584549
Gynecol Oncol. 2006 Jan;100(1):101-6
pubmed: 16157366
Mod Pathol. 2020 Jan;33(1):118-127
pubmed: 31477811
Clin Obstet Gynecol. 2011 Jun;54(2):292-304
pubmed: 21508698
Clin Cancer Res. 2020 Aug 1;26(15):3928-3935
pubmed: 32601075
J Clin Oncol. 2022 Jan 10;:JCO2102050
pubmed: 35007153
Int J Gynecol Pathol. 2012 May;31(3):211-21
pubmed: 22498937
Mod Pathol. 2013 Dec;26(12):1605-12
pubmed: 23765245
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Int J Gynecol Pathol. 2021 May 1;40(3):263-271
pubmed: 32897955
Clin Cancer Res. 2017 Oct 1;23(19):5836-5845
pubmed: 28679774